ERAS · Erasca, Inc.
$14.39
+2.49% last session
End-of-day data · close of 2026-10-23
Market cap
$5B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-23.1
Dividend yield
0.0%
Beta
0.62
Avg volume
4M
Employees
0K
Daily Change %
2.49%
5 Days Change
5.65%
10 Days Change
-2.11%
30 Days Change
-0.90%
60 Days Change
-18.98%
Month to Day Change
-1.30%
Year to Day Change
286.83%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ERAS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-14
Latest call per bank · past 12 months
Bank of America
Neutral$20.00
+39.0% vs priceMorgan Stanley
Equal-Weight$21.00
+45.9% vs priceJP Morgan
Overweight$25.00
+73.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Bank of America | Maintains | Neutral | $18.00 → $20.00 |
| 2026-08-13 | Guggenheim | Maintains | Buy | $20.00 → $21.00 |
| 2026-08-12 | HC Wainwright & Co. | Maintains | Buy | $18.00 → $22.00 |
| 2026-07-20 | Morgan Stanley | Maintains | Equal-Weight | $12.00 → $21.00 |
| 2026-07-14 | Bank of America | Maintains | Neutral | $16.00 → $18.00 |
| 2026-06-04 | Bank of America | Upgrade | Underperform → Neutral | $9.00 → $16.00 |
| 2026-05-12 | Mizuho | Maintains | Outperform | $28.00 → $26.00 |
| 2026-04-27 | Stifel | Maintains | Buy | $20.00 → $30.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 8.9% below the 50-day MA ($15.79).
- bearish: Price vs 200-day MA: Trading 2.8% below the 200-day MA ($14.80).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.04) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($2.20) and high ($22.47).
ERAS Price Chart
Loading chart for ERAS…
Fundamentals
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.